Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow
Abstract
Human umbilical cord perivascular cells (HUCPVCs) have been shown to have a high proliferative potential and the capacity to differentiate into an osteogenic phenotype. HUCPVCs have thus been considered a possible extra-embryonic mesenchymal stem cell (MSC) source for cell-based therapies. To assess this potential, we compared HUCPVCs to the “gold standard” bone marrow mesenchymal stromal cells (BMSCs) with respect to their proliferation, differentiation, and transfection capacities. HUCPVCs showed a higher proliferative potential than BMSCs and were capable of osteogenic, chondrogenic, and adipogenic differentiation. Interestingly, osteogenic differentiation of HUCPVCs proceeded more rapidly than BMSCs. Additionally, HUCPVCs expressed higher levels of CD146, a putative MSC marker, relative to BMSCs. HUCPVCs showed comparable transfection efficiency as BMSCs using a nucleofection method but were more amenable to transfection with liposomal methods (FuGENE). Gene array analysis showed that HUCPVCs also expressed Wnt signaling pathway genes that have been implicated in the regulation of MSCs. The similar characteristics between HUCPVCs and MSCs support the applicability of HUCPVCs for cell-based therapies. Disclosure of potential conflicts of interest is found at the end of this article.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MSCs vary in morphology, tri-lineage differentiation potential, proliferation rates, and immunomodulatory properties across different donors, tissue sources, subpopulations, and individual cells, referred to as heterogeneity.
“Of note, MSCs vary in morphology, tri-lineage differentiation potential, proliferation rates, and immunomodulatory properties across different donors, tissue sources, subpopulations, and individual cells, referred to as heterogeneity [178, 308–310].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [308]
Allogeneic UC-MSCs have many advantages over BM-MSCs and AD-MSCs, including wide availability, ethical considerations, safety (lower risk of viral transmission and less pronounced immune response), and superior characteristics (more primitive and higher proliferative capacity).
“Allogeneic UC-MSCs have many advantages over BM-MSCs and AD-MSCs, including 1) wide availability, as they can be obtained from the discarded UC, enabling large-scale production without donor attrition; 2) ethical considerations, as they are easier and less invasive extraction processes with no ethical concerns; 3) safety, as they carry a lower risk of viral transmission and elicit a less pronounce”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [308]
Cited by
Sorted by citations
Covas, D. T., Panepucci, R. A., Fontes, A. M., Silva, W. A., Orellana, M. D., Freitas, M. C. C., Neder, L., Santos, A. R. D., Peres, L. C., Jamur, M. C., et al. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2007.12.015 · Cited by 610 · see citing works
Du, W. J., Chi, Y., Yang, Z. X., Li, Z. J., Cui, J. J., Song, B. Q., Li, X., Yang, S. G., Han, Z. B., & Han, Z. C. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0418-9 · Cited by 200 · see citing works
Majore, I., Moretti, P., Stahl, F., Hass, R., & Kasper, C. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9165-y · Cited by 167 · see citing works
Salazar, K. D., Lankford, S. M., & Brody, A. R. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90347.2008 · Cited by 134 · see citing works
Boyette, L. B., Creasey, O. A., Guzik, L., Lozito, T., & Tuan, R. S. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0079 · Cited by 121 · see citing works
Self-citationLi, X., Xu, Z., Bai, J., Yang, S., Zhao, S., Zhang, Y., Chen, X., & Wang, Y. (2016) · Stem Cells International · doi:10.1155/2016/7495135 · Cited by 58 · see citing works
Miranda, J. P., Filipe, E., Fernandes, A. S., Almeida, J. M., Martins, J. P., De La Fuente, A., Abal, M., Barcia, R. N., Cruz, P., Cruz, H., et al. (2015) · Cell Transplantation · doi:10.3727/096368913x676231 · Cited by 38 · see citing works
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2 · see citing works
“Of note, MSCs vary in morphology, tri-lineage differentiation potential, proliferation rates, and immuno-modulatory properties across different donors, tissue sources, subpopulations, and individual cells, referred to as heterogeneity [178, 308–310].”
- Authors
- Baksh, D., Yao, R., & Tuan, R. S.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Tuan, Rocky S.
- ORCID
- Tuan, Rocky S.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 25
- Issue
- 6
- Pages
- 1384-1392
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W1976906682
- Cited by
- 1,058
- References
- 0
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 47 · 2023: 37 · 2022: 41 · 2021: 72 · 2020: 54 · 2019: 61 · 2018: 62 · 2017: 75 · 2016: 72 · 2015: 68 · 2014: 70 · 2013: 94 · 2012: 67
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Topics
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- human umbilical cord perivascular cells, bone marrow mesenchymal stromal cells, mesenchymal stem cells, osteogenic differentiation, chondrogenic differentiation, adipogenesis, multilineage differentiation, cell proliferation, transfection efficiency, CD146, Wnt signaling, cell therapy
- MeSH terms
- Bone Marrow Cells, Cell Differentiation, Cells, Cultured, Humans, Transfection, Umbilical Cord, Signal Transduction, Immunophenotyping, Cell Lineage, Cell Proliferation, Wnt Proteins, CD146 Antigen, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
